CRISPR-Cas9: A method for establishing rat models of drug metabolism and pharmacokinetics - ScienceDirect

Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease

Small-molecule modulators of TRMT2A decrease PolyQ aggregation and PolyQ-induced cell death - Computational and Structural Biotechnology Journal

Pharmacological inhibition of DNA methylation attenuates pressure overload-induced cardiac hypertrophy in rats - Journal of Molecular and Cellular Cardiology

Methods of CRISPR/Cas9 technology to construct animal models. (A)

Protective Effect of Natural Products against Huntington's Disease: An Overview of Scientific Evidence and Understanding Their Mechanism of Action

Clinical trials and promising preclinical applications of CRISPR/Cas gene editing - ScienceDirect

The Pharmacokinetics and Pharmacodynamics of A Novel Recombinant Activated Human Factor VII, GEN-0828, in Hemophilia B Mice - Journal of Pharmaceutical Sciences

Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities - The Lancet Neurology

The Pharmacokinetics and Pharmacodynamics of A Novel Recombinant Activated Human Factor VII, GEN-0828, in Hemophilia B Mice - Journal of Pharmaceutical Sciences